Journal of Clinical Oncology, Vol 15, 1906-1915, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

L Gianni, L Vigano, A Locatelli, G Capri, A Giani, E Tarenzi and G Bonadonna
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy. GIANNI@istitutotumori.mi.it

PURPOSE: We performed a pharmacologic investigation of paclitaxel (PTX) infused over 3 hours and bolus doxorubicin (DOX) to assess the role of sequence, interval between drugs, and duration of doxorubicin infusion on paclitaxel and anthracycline plasma disposition. We also explored possible mechanisms of pharmacokinetic interference involving the physiologic role of the multidrug resistance phenotype in anthracycline and taxane biliary excretion. PATIENTS AND METHODS: Pharmacokinetics was performed in 80 cycles and 36 women with previously untreated metastatic breast cancer. PTX, DOX, and their metabolites 6 alpha- hydroxyl-PTX (6 alpha OH-PTX) and doxorubicinol (DOL) were measured by high-pressure liquid chromatography (HPLC). Human breast cancer MCF-7 wild-type (WT) and resistant (TH) cell lines were cultured in whole human plasma to study anthracycline retention after treatment with different combinations of PTX, Cremophor EL (CEL) (PEG35 castor oil; BASF, Parsippany, NJ), and DOX. RESULTS: Pharmacokinetic interference between PTX and DOX was responsible for nonlinearity of DOX plasma disposition and increased concentrations of DOX and DOL. These effects were PTX dose-dependent, DOX concentration-dependent, and likely a result of interference at the level of liver elimination. In view of the physiologic role of P-glycoproteins (P-gp) in xenobiotic biliary excretion, retention of DOX was assessed in MCF-7 WT and MCF-7 TH cells. Intracellular was significantly higher in MCF-7 WT than MCF-7 TH (P < .05). However, concomitant exposure to DOX, PTX, and CEL caused similar DOX retention in both MCF-7 WT and TH cells. CONCLUSION: PTX, as clinically formulated in CEL, is responsible for a nonlinear disposition of DOX and DOL. Nonlinearity is PTX- and DOX-dependent, and possibly caused by competition for biliary excretion of taxanes and anthracyclines mediated by P-gp. Nonlinearity indicates that even minor modifications of dose and infusion duration of DOX and PTX may lead to unpredictable pharmacodynamic consequences. The postulated role of P-gp suggests that CEL is clinically active, and advises caution in designing combinations of PTX with other drugs that are substrate for P- gp.

This article has been cited by other articles:

				P. Menna, E. Salvatorelli, and G. Minotti Doxorubicin Degradation in Cardiomyocytes J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 408 - 419. [Abstract] [Full Text] [PDF]

				E. Salvatorelli, P. Menna, L. Gianni, and G. Minotti Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 790 - 800. [Abstract] [Full Text] [PDF]

				T. L'Ecuyer, S. Sanjeev, R. Thomas, R. Novak, L. Das, W. Campbell, and R. V. Heide DNA damage is an early event in doxorubicin-induced cardiac myocyte death Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1273 - H1280. [Abstract] [Full Text] [PDF]

				E. Salvatorelli, P. Menna, S. Cascegna, G. Liberi, A. M. Calafiore, L. Gianni, and G. Minotti Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 424 - 433. [Abstract] [Full Text] [PDF]

				C. C. Chua, X. Liu, J. Gao, R. C. Hamdy, and B. H. L. Chua Multiple actions of pifithrin-{alpha} on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2606 - H2613. [Abstract] [Full Text] [PDF]

				E. Salvatorelli, S. Guarnieri, P. Menna, G. Liberi, A. M. Calafiore, M. A. Mariggio, A. Mordente, L. Gianni, and G. Minotti Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart: RELATIVE IMPORTANCE OF VESICULAR SEQUESTRATION AND IMPAIRED EFFICIENCY OF ELECTRON ADDITION J. Biol. Chem., April 21, 2006; 281(16): 10990 - 11001. [Abstract] [Full Text] [PDF]

				R. E. Langley, J. Carmichael, A. L. Jones, D. A. Cameron, W. Qian, B. Uscinska, A. Howell, and M. Parmar Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01 J. Clin. Oncol., November 20, 2005; 23(33): 8322 - 8330. [Abstract] [Full Text] [PDF]

				M. Martin, T. Pienkowski, J. Mackey, M. Pawlicki, J.-P. Guastalla, C. Weaver, E. Tomiak, T. Al-Tweigeri, L. Chap, E. Juhos, et al. Adjuvant Docetaxel for Node-Positive Breast Cancer N. Engl. J. Med., June 2, 2005; 352(22): 2302 - 2313. [Abstract] [Full Text] [PDF]

				E. Briasoulis, G. Pentheroudakis, V. Karavasilis, E. Tzamakou, D. Rammou, and N. Pavlidis Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors Ann. Onc., October 1, 2004; 15(10): 1566 - 1573. [Abstract] [Full Text] [PDF]

				J. Gligorov and J. P. Lotz Preclinical Pharmacology of the Taxanes: Implications of the Differences Oncologist, June 2, 2004; 9(suppl_2): 3 - 8. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				G. Corna, P. Santambrogio, G. Minotti, and G. Cairo Doxorubicin Paradoxically Protects Cardiomyocytes against Iron-mediated Toxicity: ROLE OF REACTIVE OXYGEN SPECIES AND FERRITIN J. Biol. Chem., April 2, 2004; 279(14): 13738 - 13745. [Abstract] [Full Text] [PDF]

				A. Cartoni, P. Menna, E. Salvatorelli, D. Braghiroli, R. Giampietro, F. Animati, A. Urbani, P. Del Boccio, and G. Minotti Oxidative Degradation of Cardiotoxic Anticancer Anthracyclines to Phthalic Acids: NOVEL FUNCTION FOR FERRYLMYOGLOBIN J. Biol. Chem., February 13, 2004; 279(7): 5088 - 5099. [Abstract] [Full Text] [PDF]

				G. Bianchi, J. Albanell, W. Eiermann, G. Vitali, D. Borquez, L. Vigano, R. Molina, G. Raab, A. Locatelli, B. Vanhauwere, et al. Pilot Trial of Trastuzumab Starting with or after the Doxorubicin Component of a Doxorubicin plus Paclitaxel Regimen for Women with HER2-Positive Advanced Breast Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5944 - 5951. [Abstract] [Full Text] [PDF]

				M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF]

				V. Hess, M. W. Verrill, C. C. Bomphray, M. M. Vaughan, M. Allen, and M. E. Gore Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma Ann. Onc., April 1, 2003; 14(4): 638 - 642. [Abstract] [Full Text] [PDF]

				D. Rischin, S. P. Ackland, J. Smith, M. B. Garg, S. Clarke, M. J. Millward, G. C. Toner, and J. Zalcberg Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics Ann. Onc., November 1, 2002; 13(11): 1810 - 1818. [Abstract] [Full Text] [PDF]

				S. H. Giordano, D. J. Booser, J. L. Murray, N. K. Ibrahim, Z. U. Rahman, V. Valero, R. L. Theriault, M. F. Rosales, E. Rivera, D. Frye, et al. A Detailed Evaluation of Cardiac Toxicity: A Phase II Study of Doxorubicin and One- or Three-Hour-Infusion Paclitaxel in Patients with Metastatic Breast Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3360 - 3368. [Abstract] [Full Text] [PDF]

				L. Biganzoli, T. Cufer, P. Bruning, R. Coleman, L. Duchateau, A.H. Calvert, T. Gamucci, C. Twelves, P. Fargeot, R. Epelbaum, et al. Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial J. Clin. Oncol., July 15, 2002; 20(14): 3114 - 3121. [Abstract] [Full Text] [PDF]

				S. Fogli, R. Danesi, A. Gennari, S. Donati, P. F. Conte, and M. Del Tacca Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer Ann. Onc., June 1, 2002; 13(6): 919 - 927. [Abstract] [Full Text] [PDF]

				P. Vici, G. Colucci, V. Gebbia, A. Amodio, F. Giotta, F. Belli, F. Conti, N. Gebbia, G. Pezzella, M. R. Valerio, et al. First-Line Treatment With Epirubicin and Vinorelbine in Metastatic Breast Cancer J. Clin. Oncol., June 1, 2002; 20(11): 2689 - 2694. [Abstract] [Full Text] [PDF]

				G. Lunardi, M. Venturini, M. O. Vannozzi, G. Tolino, L. Del Mastro, C. Bighin, G. Schettini, and M. Esposito Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer Ann. Onc., February 20, 2002; 13(2): 280 - 285. [Abstract] [Full Text] [PDF]

				G. Minotti, R. Ronchi, E. Salvatorelli, P. Menna, and G. Cairo Doxorubicin Irreversibly Inactivates Iron Regulatory Proteins 1 and 2 in Cardiomyocytes: Evidence for Distinct Metabolic Pathways and Implications for Iron-mediated Cardiotoxicity of Antitumor Therapy Cancer Res., December 1, 2001; 61(23): 8422 - 8428. [Abstract] [Full Text] [PDF]

				A. Henningsson, M. O. Karlsson, L. Vigano, L. Gianni, J. Verweij, and A. Sparreboom Mechanism-Based Pharmacokinetic Model for Paclitaxel J. Clin. Oncol., October 15, 2001; 19(20): 4065 - 4073. [Abstract] [Full Text] [PDF]

				M. S. Aapro Adjuvant Therapy of Primary Breast Cancer: A Review of Key Findings from the 7th International Conference, St. Gallen, February 2001 Oncologist, August 1, 2001; 6(4): 376 - 385. [Abstract] [Full Text] [PDF]

				D. Khayat, P. Chollet, E. C. Antoine, S. Monfardini, G. Ambrosini, A. Benhammouda, M.-F. Mazen, R. Sorio, O. Borg-Olivier, A. Riva, et al. Phase II Study of Sequential Administration of Docetaxel Followed by Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer J. Clin. Oncol., July 15, 2001; 19(14): 3367 - 3375. [Abstract] [Full Text] [PDF]

				G. Minotti, A. Saponiero, S. Licata, P. Menna, A. M. Calafiore, G. Teodori, and L. Gianni Paclitaxel and Docetaxel Enhance the Metabolism of Doxorubicin to Toxic Species in Human Myocardium Clin. Cancer Res., June 1, 2001; 7(6): 1511 - 1515. [Abstract] [Full Text] [PDF]

				J. Crown Docetaxel: Overview of an Active Drug for Breast Cancer Oncologist, June 1, 2001; 6(2008): 1 - 4. [Abstract] [Full Text] [PDF]

				J.-M. Nabholtz and A. Riva Taxane/Anthracycline Combinations: Setting a New Standard in Breast Cancer? Oncologist, June 1, 2001; 6(2008): 5 - 12. [Abstract] [Full Text] [PDF]

				C. Sessa and O. Pagani Docetaxel and Epirubicin in Advanced Breast Cancer Oncologist, June 1, 2001; 6(2008): 13 - 16. [Abstract] [Full Text] [PDF]

				R. Advani, G. A. Fisher, B. L. Lum, J. Hausdorff, J. Halsey, M. Litchman, and B. I. Sikic A Phase I Trial of Doxorubicin, Paclitaxel, and Valspodar (PSC 833), a Modulator of Multidrug Resistance Clin. Cancer Res., May 1, 2001; 7(5): 1221 - 1229. [Abstract] [Full Text]

				G. Grasselli, L. Vigano, G. Capri, A. Locatelli, E. Tarenzi, C. Spreafico, A. Bertuzzi, A. Giani, C. Materazzo, S. Cresta, et al. Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2222 - 2231. [Abstract] [Full Text] [PDF]

				J. Jassem, T. Pienkowski, A. Pluzanska, S. Jelic, V. Gorbunova, Z. Mrsic-Krmpotic, J. Berzins, T. Nagykalnai, N. Wigler, J. Renard, et al. Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial J. Clin. Oncol., March 15, 2001; 19(6): 1707 - 1715. [Abstract] [Full Text] [PDF]

				G. F. Fleming, J. M. Fowler, S. E. Waggoner, L. J. Copeland, B. E. Greer, I. Horowitz, G. Sutton, R. J. Schilder, P. M. Fracasso, H. G. Ball, et al. Phase I Trial of Escalating Doses of Paclitaxel Combined With Fixed Doses of Cisplatin and Doxorubicin in Advanced Endometrial Cancer and Other Gynecologic Malignancies: A Gynecologic Oncology Group Study J. Clin. Oncol., February 15, 2001; 19(4): 1021 - 1029. [Abstract] [Full Text] [PDF]

				J. M. Nabholtz, J. R. Mackey, M. Smylie, A. Paterson, D. R. Noel, T. Al-Tweigeri, K. Tonkin, S. North, N. Azli, and A. Riva Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer J. Clin. Oncol., January 15, 2001; 19(2): 314 - 321. [Abstract] [Full Text] [PDF]

				K. Itoh, Y. Sasaki, H. Fujii, H. Minami, T. Ohtsu, H. Wakita, T. Igarashi, Y. Watanabe, Y. Onozawa, M. Kashimura, et al. Study of Dose Escalation and Sequence Switching of Administration of the Combination of Docetaxel and Doxorubicin in Advanced Breast Cancer Clin. Cancer Res., October 1, 2000; 6(10): 4082 - 4090. [Abstract] [Full Text]

				C. D. Britten, S. D. Baker, L. J. Denis, T. Johnson, R. Drengler, L. L. Siu, K. Duchin, J. Kuhn, and E. K. Rowinsky Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to Paclitaxel Clin. Cancer Res., September 1, 2000; 6(9): 3459 - 3468. [Abstract] [Full Text]

				J. Crown and W. Palmby Docetaxel: use in non--small cell lung cancer and metastatic breast cancer and formulation update Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S11 - S21. [Abstract] [PDF]

				D. Frame Introduction to taxane pharmacokinetics and pharmacodynamics Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S23 - S27. [Abstract] [PDF]

				J. A. Sparano, A. O'Neill, P. L. Schaefer, C. I. Falkson, and W. C. Wood Phase II Trial of Doxorubicin and Docetaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: Eastern Cooperative Oncology Group Study E1196 J. Clin. Oncol., June 12, 2000; 18(12): 2369 - 2377. [Abstract] [Full Text] [PDF]

				M. Venturini, G. Lunardi, L. Del Mastro, M. O. Vannozzi, G. Tolino, G. Numico, M. Viale, I. Pastrone, C. Angiolini, G. Bertelli, et al. Sequence Effect of Epirubicin and Paclitaxel Treatment on Pharmacokinetics and Toxicity J. Clin. Oncol., May 10, 2000; 18(10): 2116 - 2125. [Abstract] [Full Text] [PDF]

				R. Paridaens, L. Biganzoli, P. Bruning, J. G. M. Klijn, T. Gamucci, S. Houston, R. Coleman, J. Schachter, A. Van Vreckem, R. Sylvester, et al. Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over J. Clin. Oncol., February 14, 2000; 18(4): 724 - 724. [Abstract] [Full Text] [PDF]

				A. Gennari, B. Salvadori, S. Donati, C. Bengala, C. Orlandini, R. Danesi, M. Del Tacca, P. Bruzzi, and P. F. Conte Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors J. Clin. Oncol., November 1, 1999; 17(11): 3596 - 3602. [Abstract] [Full Text] [PDF]

				M. Esposito, M. Venturini, M.O. Vannozzi, G. Tolino, G. Lunardi, O. Garrone, C. Angiolini, M. Viale, M. Bergaglio, L. Del Mastro, et al. Comparative Effects of Paclitaxel and Docetaxel on the Metabolism and Pharmacokinetics of Epirubicin in Breast Cancer Patients J. Clin. Oncol., April 1, 1999; 17(4): 1132 - 1132. [Abstract] [Full Text] [PDF]

				A. Sparreboom, L. van Zuylen, E. Brouwer, W. J. Loos, P. de Bruijn, H. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij Cremophor EL-mediated Alteration of Paclitaxel Distribution in Human Blood: Clinical Pharmacokinetic Implications Cancer Res., April 1, 1999; 59(7): 1454 - 1457. [Abstract] [Full Text] [PDF]

				J. A. Sparano, J. Speyer, W. J. Gradishar, L. Liebes, R. Sridhara, S. Mendoza, D. Fry, and M. J. Egorin Phase I Trial of Escalating Doses of Paclitaxel Plus Doxorubicin and Dexrazoxane in Patients With Advanced Breast Cancer J. Clin. Oncol., March 1, 1999; 17(3): 880 - 880. [Abstract] [Full Text] [PDF]

				S. G. Diab, S. D. Baker, A. Joshi, H. A. Burris, P. W. Cobb, M. A. Villalona-Calero, S. G. Eckhardt, G. R. Weiss, G. I. Rodriguez, R. Drengler, et al. A Phase I and Pharmacokinetic Study of Losoxantrone and Paclitaxel in Patients with Advanced Solid Tumors Clin. Cancer Res., February 1, 1999; 5(2): 299 - 308. [Abstract] [Full Text] [PDF]

				E. A. Perez Paclitaxel in Breast Cancer Oncologist, December 1, 1998; 3(6): 373 - 389. [Abstract] [Full Text]